Cargando…
Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies
Hypertension with vascular endothelial growth factor (VEGF) receptor inhibitors is associated with superior treatment outcomes for advanced cancer patients. To determine whether increased doses of sorafenib cause incremental increases in blood pressure (BP) we measured 12-hour ambulatory BP in 41 no...
Autores principales: | Karovic, Sanja, Wen, Yujia, Karrison, Theodore G., Bakris, George L., Levine, Matthew R., House, Larry K., Wu, Kehua, Thomeas, Vasiliki, Rudek, Michelle A., Wright, John J., Cohen, Ezra E.W., Fleming, Gini F., Ratain, Mark J., Maitland, Michael L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165641/ https://www.ncbi.nlm.nih.gov/pubmed/24637941 http://dx.doi.org/10.1038/clpt.2014.63 |
Ejemplares similares
-
Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
por: Karovic, S, et al.
Publicado: (2016) -
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial
por: Maitland, Michael L., et al.
Publicado: (2018) -
Estimation of renal cell carcinoma treatment effects from disease progression modeling
por: Maitland, Michael L., et al.
Publicado: (2012) -
Model‐based approach to identify predictors of paclitaxel‐induced myelosuppression in “real‐world” administration
por: Salem, Ahmed M., et al.
Publicado: (2023) -
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling
por: Li, CH, et al.
Publicado: (2016)